Hoffmann La Roche Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hoffmann La Roche stocks.

Hoffmann La Roche Stocks Recent News

Date Stock Title
Nov 20 HALO Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 19 SGMO Sangamo stock climbs 12% post-market on FDA update for ST-503
Nov 19 SGMO Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Nov 19 HALO 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Nov 19 HALO HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Nov 19 HALO Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
Nov 19 HALO Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Nov 18 HALO Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Nov 17 HALO Halozyme plans to finance $2.1B takeover of Evotech in cash: report
Nov 17 HALO Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Nov 15 HALO Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Nov 15 HALO Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Nov 15 HALO Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
Nov 15 SGMO Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Nov 15 HALO Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Nov 15 HALO Halozyme bids for Evotec; BeiGene gets a new name
Nov 14 HALO Germany’s Evotec Gets Takeover Interest From Halozyme
Nov 14 HALO Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
Hoffmann La Roche

F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based Ventana. Roche's revenues during fiscal year 2016 were 50.58 billion Swiss francs, or approximately US$51 billion. Roche is the third-largest pharmaceutical company worldwide.
Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares. Roche is one of the few companies increasing their dividend every year, for 2016 as the 30th consecutive year. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Browse All Tags